

<b>Study</b>	<b>Prospective Study of Proton Beam Craniospinal Radiotherapy in Children with Newly-Diagnosed Medulloblastoma - Assessment of Acute and Long Term Sequelae and quality of life</b>
<i>Principle Investigator</i>	Joo Young Kim, M.D.
<i>Contact</i>	Joo Young Kim, M.D. <a href="mailto:jooyoungcasa@ncc.re.kr">jooyoungcasa@ncc.re.kr</a> ; +82-31-920-1724
<i>Additional Info</i>	
<i>Institution</i>	National Cancer Center Korea
<i>Recruitment Status</i>	Study Start Date: March 15, 2005  Estimated Primary Completion Date: April 7, 2015  Estimated Study Completion Date: December 2016  Estimated Enrollment: Ongoing, but not recruiting
<i>Study Purpose</i>	PURPOSE: This phase II trial is studying how well proton beam radiation therapy works in treating young patients who have undergone biopsy or surgery for medulloblastoma or pineoblastoma.
<i>Primary Aims</i>	1. To assess the acute and late sequelae and the quality of life of the children treated by proton beam treatment
<i>Secondary Aims</i>	To determine the tumor control probability of the children treated proton beam therapy compared with the historical control rates.  To evaluate the radiation (and chemotherapy) induced neurocognitive and endocrine function in a systematic way.  To improve compliance with long-term quality of life and functional status data submission.
<i>Methods</i>	normalization point/dose prescription : 23.4 - 36 Gy equivalent dose (GyE)/13-20F to the target volume using 1.8 GyE equivalent fractional dose according to the risk of the patients  AR (Average-risk) : 32 GyE/16F boost to the primary site, 23.4 GyE CSRT --> primary site 55.4 GyE/29F/6wks  HR(High-risk): 20 GyE/10F boost to the primary site, 36 GyE CSRT --> 56 GyE/30F/6wks  M1 : 36 GyE CSRT  M2-3 : 36GyE for the children age<5, 39GyE for children≥5  Boost to the metastatic site up to 46.8 GyE ~ 54 GyE can be given depending on the age and the disease sites

<b>Study</b>	<b>Prospective Study of Proton Beam Craniospinal Radiotherapy in Children with Newly-Diagnosed Medulloblastoma - Assessment of Acute and Long Term Sequelae and quality of life</b>
<i>Eligibility</i>	<p>Patients in <math>3 &lt; \text{Age} \leq 18</math> with M0~M3 treated under the KSPNO-M051/M052 scheme</p> <p><math>1 \leq \text{Age} \leq 3</math> with M1~3 with planned radiotherapy after PBSCT or patients with less than 50% response to pre-PBSCT chemotherapy</p> <p>Any age with relapsed disease in the craniospinal axis who was not irradiated in the initial treatment- For these group of patients, the proton beam treatment described here is either used as a treatment guideline, or as a component of KSPNO-53</p> <p>Other primitive neuroectodermal tumors (PNET) and atypical teratoid rhabdoid tumors (ATRT)</p> <p>Histologic Confirmation for medulloblastoma; written informed consent</p>
<i>Exclusion Criteria</i>	<p>Patients who were irradiated to the tolerance dose of the neural tissues of the involved site</p> <p>Patients who are pregnant or breast-feeding will not be eligible.</p>